Skip to main content

Roivant Sciences: How we invest and partner with biopharma companies (EN)

Date

08.06.22

Time

17:30 - 20:15

Location

Markthalle
Viaduktstrasse 10, 4051 Basel

Language

English
Share event
Martyna Wroblewska

Organizer

Martyna Wroblewska
Phone
+41 79 645 67 18
Email
martyna.wroblewska@baselaunch.ch

Roivant Sciences: How we invest and partner with biopharma companies to lead the transition to a more data-driven, patient-centric, and value-oriented health system (EN)

We are back for in person events! Join us at this biotech networking event empowered by Innosuisse featuring Roivant Sciences!

Roivant Sciences is an integrated pharma-tech business that develops transformative medicines faster by building technologies and developing talent in creative ways. Roivant was only formed 8 years ago and quickly muscled its way to the top cadre of biopharma companies. Leveraging the Roivant platform they launch “Vants” – nimble and focused biopharmaceutical and health technology companies. With the addition of Roivant Discovery in 2021, Roivant Sciences now possesses capabilities throughout the full value chain for the discovery, development, and commercialization of novel therapeutics.

Join us at this event with Roivant Sciences to hear about their partnering strategy and investments in novel technologies. You will also hear how Roivant is able to grow a global biopharma company from scratch into a leader in the field while still maintaining its entrepreneurial edge and how they are improving the delivery of healthcare to patients by treating every inefficiency as an opportunity.

Program

17:30

Introduction
Martyna Wroblewska, BaseLaunch

17:40

1. Introduction to Roivant Sciences
An 8 year old, clinical stage, publicly-traded biopharmaceutical company with the mission to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity.

Speaker: Christian Mauriand, Global Head of Corporate Development

 

2. Roivant Discovery Engine
Accelerating the discovery of transformative medicines through the interplay of our leading Physics & AI-based computational, Heterobifunctional and Covalent platforms.

Speaker: Eric Valeur, Vice President, Head of Drug Discovery

 

3. BD Activities and Pipeline Overview
Partnering strategy and breadth of clinical stage assets within “Vants” – nimble and focused biopharmaceutical and health technology companies

Speaker: Niharika Sharma, Principal, Corporate Development

18:45

Q&A with the speakers

19:15

Networking Opportunity

Participation is free, however registration is required before June 6th, 2022.

Our partner